000 04177nam a22003615i 4500
001 279979
003 MX-SnUAN
005 20160429154005.0
007 cr nn 008mamaa
008 150903s2007 xxu| o |||| 0|eng d
020 _a9780387715223
_99780387715223
024 7 _a10.1007/9780387715223
_2doi
035 _avtls000332154
039 9 _a201509030217
_bVLOAD
_c201404122039
_dVLOAD
_c201404091809
_dVLOAD
_y201402041022
_zstaff
040 _aMX-SnUAN
_bspa
_cMX-SnUAN
_erda
050 4 _aRM1-950
100 1 _aCuello, A. Claudio.
_eautor
_9304601
245 1 0 _aPharmacological Mechanisms in Alzheimer's Therapeutics /
_cby A. Claudio Cuello.
264 1 _aNew York, NY :
_bSpringer New York,
_c2007.
300 _brecurso en línea.
336 _atexto
_btxt
_2rdacontent
337 _acomputadora
_bc
_2rdamedia
338 _arecurso en línea
_bcr
_2rdacarrier
347 _aarchivo de texto
_bPDF
_2rda
500 _aSpringer eBooks
505 0 _aOverview of the Alzheimer's Disease Pathology and Potential Therapeutic Targets -- Trial Designs and Outcomes to Monitor Novel Therapeutics in Alzheimer's Disease -- The Pharmacological Treatment of Alzheimer's Disease with Cholinesterase Inhibitors and Memantine -- M1 Muscarinic Agonists: A Comprehensive Therapy Against Major Hallmarks of Alzheimer's Disease -- Cholinergic Neurodegeneration in Alzheimer's Disease: Basis for Nerve Growth Factor Therapy -- The Rationale for Glutamatergic Therapy in Alzheimer's Disease -- Secretases as Pharmacological Targets in Alzheimer's Disease -- ?-Secretase as a Target for Alzheimer's Disease -- The Rationale for an Immunological Approach to Alzheimer's Therapeutics -- Neuroinflammation, Alzheimer Disease, and Other Aging Disorders -- Nonsteroidal Anti-inflammatory Drugs (NSAIDs) and Derived A?42-Lowering Molecules for Treatment and Prevention of Alzheimer's Disease (AD) -- The Potential Application of Antioxidant Agents in Alzheimer Disease Therapeutics -- Apolipoprotein E: A Potent Gene-Based Therapeutic Target for the Treatment of Sporadic Alzheimer's Disease -- Tau Pathology as a Target in Alzheimer's Therapeutics -- Design of Inhibitors of Amyloid-? Misfolding and Aggregation for Alzheimer's Therapy -- Potential Applications of Glycosaminoglycan-Related Compounds in Alzheimer's Disease -- Multifunctional Neuroprotective Drugs for the Treatment of Alzheimer's Disease -- Interpreting Clinical Studies of Putative Therapeutics for Alzheimer's Disease: The Case of Statins and NSAIDs.
520 _aAlzheimer’s is the most common dementia in the elderly. The need for effective therapy of dementia is greater than ever, but there is not, as yet, a drug therapy which can stop or reverse the clinical consequences. There is, however, a great deal of anticipation on the imminent development of effective, disease-modifying therapies. The remarkable progress made by the scientific community in unraveling molecular and cellular aspects of the Alzheimer’s pathology has allowed the identification of a number of promising targets for drug development. Investigation of these targets and the evolution of ongoing strategies to develop efficacious therapies for this devastating neurodegenerative condition is the central theme of Pharmacological Mechanisms in Alzheimer’s Therapeutics. The current and future therapies based on this new knowledge of the Alzheimer’s pathology are dealt with by contributors who have been most influential in bringing this new knowledge and in the development of experimental and presently applied therapies. The book should be of interest to medical professionals and basic scientists alike since it provides ideas about current trends in Alzheimer’s therapeutics to the general public.
590 _aPara consulta fuera de la UANL se requiere clave de acceso remoto.
710 2 _aSpringerLink (Servicio en línea)
_9299170
776 0 8 _iEdición impresa:
_z9780387715216
856 4 0 _uhttp://remoto.dgb.uanl.mx/login?url=http://dx.doi.org/10.1007/978-0-387-71522-3
_zConectar a Springer E-Books (Para consulta externa se requiere previa autentificación en Biblioteca Digital UANL)
942 _c14
999 _c279979
_d279979